# US 2021/0330646 A1 · Fascin binding compounds for spinogenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330646 A1
- Document ID: US20210330646A1
- Status: Published application
- Kind: A1
- Application number: 17/271,163
- Filed: 2019-08-27
- Published: 2021-10-28
- Earliest claimed: 2018-08-27
- Assignees: Spinogenix, Inc.
- Applicants: Spinogenix, Inc.
- Inventors: Stella T. SARRAF; Vincent F. SIMMON; Peter W. VANDERKLISH
- Web page: https://patentgrep.com/patent/US20210330646A1

## CPC

- A61K 31/426: 1,3-Thiazoles
- A61K 31/335: having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K 31/416: condensed with carbocyclic ring systems, e.g. indazole
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/497: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In some embodiments, a method of promoting spinogenesis in a patient is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a compound which binds to fascin at least at binding site 2 or binding site 3.

## Claims

### Claim 1

A method of promoting spinogenesis in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a compound which binds to fascin at least at binding site 2.

### Claim 2

A method of promoting spinogenesis in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a compound which binds to fascin at least at binding site 3.

### Claim 3

A method of promoting spinogenesis in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I:
or a pharmaceutically acceptable salt thereof;
wherein A1, A2, A3, A4, A5 and A6 are independently selected from the group consisting of CH, CR3 and N, provided that no more than four of A1, A2, A3, A4, A5 and A6 are N;
R1 is selected from the group consisting of phenyl, 5-membered heteroaryl and 6-membered heteroaryl, wherein the phenyl, 5-membered heteroaryl or 6-membered heteroaryl is optionally substituted with 1 to 3 R6;
L2 is selected from the group consisting of a covalent bond, —NR8—, —C(O)NR8—, —NR8—, —C(O)NR8—, —NR8C(O)—, —C(O)CR82—, —CR82C(O)—, —NR8CR82—, and —CR82NR8—;
R2 is H, C1-6 alkyl, 6- to 10-membered aryl or 5- to 10-membered heteroaryl; wherein the 6- to 10-membered aryl or 5- to 10-membered heteroaryl is optionally substituted with 1 to 4 R4, wherein each R4 is independently selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, phenyl (optionally substituted with C1-6 alkyl, halo, C1-6 haloalkyl, or —OH), —OH, —OR7, —SH, —SR7, —NR10R10, halo, cyano, nitro, —COH, —COR7, —CO2H, —CO2R7, —CONR10R10, —OCOR7, —OCO2R7, —OCONR10R10, —NR10COR7, —NR10CO2R7, —SOR7, —SO2R7, —SO2NR10R10, and —NR10SO2R7;
each R3 is independently selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, —OH, —OR7, —SH, —SR7, —NR10R10, halo, cyano, nitro, —COH, —COR7, —CO2H, —CO2R7, —CONR10R10, —OCOR7, —OCO2R7, —OCONR10R10, —NR10COR7, —NR10CO2R7, —SOR7, —SO2R7, —SO2NR10R10, and —NR10SO2R7;
q is 1, 2 or 3;
each R6 is independently selected from the group consisting of cyano, halo, C1-6 alkyl, C1-6 haloalkyl, and —CH2OH;
R7 is C1-6 alkyl or C1-6 haloalkyl;
R8 is hydrogen or C1-6 alkyl;
each R10 is independently hydrogen or C1-6 alkyl, or two R10 together with the atom(s) attached thereto form a 4- to 6-membered ring; and
R11 is hydrogen or R3.

### Claim 4

A method of promoting spinogenesis in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of a compound selected from a compound of formula II, formula IV, formula V, formula VII, formula VIII, formula IX, formula X, or formula XI, or a pharmaceutically acceptable salt thereof, or compound 1, compound 8, compound 9, compound 10, or compound 11, or a pharmaceutically acceptable salt thereof.

### Claim 5

A method of treating or preventing a neuronal disease or disorder comprising administering to a patient in need thereof, a therapeutically effective amount of a compound which binds to fascin at least at binding site 2.

### Claim 6

A method of treating or preventing a neuronal disease or disorder comprising administering to a patient in need thereof, a therapeutically effective amount of a compound which binds to fascin at least at binding site 3.

### Claim 7 (depends on 5, 6)

The method of claim 5 or claim 6, wherein the compound is selected from a compound of formula I, formula II, formula IV, formula V, formula VII, formula VIII, formula IX, formula X, or formula XI, or a pharmaceutically acceptable salt thereof, or compound 1, compound 8, compound 9, compound 10, or compound 11, or a pharmaceutically acceptable salt thereof.

### Claim 8

A method of treating or preventing a neuronal disease or disorder comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I:
or a pharmaceutically acceptable salt thereof;
wherein A1, A2, A3, A4, A5 and A6 are independently selected from the group consisting of CH, CR3 and N, provided that no more than four of A1, A2, A3, A4, A5 and A6 are N;
R1 is selected from the group consisting of phenyl, 5-membered heteroaryl and 6-membered heteroaryl, wherein the phenyl, 5-membered heteroaryl or 6-membered heteroaryl is optionally substituted with 1 to 3 R6;
L2 is selected from the group consisting of a covalent bond, —NR8—, —C(O)NR8—, —NR8—, —C(O)NR8—, —NR8C(O)—, —C(O)CR82—, —CR82C(O)—, —NR8CR82—, and —CR82NR8—;
R2 is H, C1-6 alkyl, 6- to 10-membered aryl or 5- to 10-membered heteroaryl; wherein the 6- to 10-membered aryl or 5- to 10-membered heteroaryl is optionally substituted with 1 to 4 R4, wherein each R4 is independently selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, phenyl (optionally substituted with C1-6 alkyl, halo, C1-6 haloalkyl, or —OH), —OH, —OR7, —SH, —SR7, —NR10R10, halo, cyano, nitro, —COH, —COR7, —CO2H, —CO2R7, —CONR10R10, —OCOR7, —OCO2R7, —OCONR10R10, —NR10COR7, —NR10CO2R7, —SOR7, —SO2R7, —SO2NR10R10, and —NR10SO2R7;
each R3 is independently selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, —OH, —OR7, —SH, —SR7, —NR10R10, halo, cyano, nitro, —COH, —COR7, —CO2H, —CO2R7, —CONR10R10, —OCOR7, —OCO2R7, —OCONR10R10, —NR10COR7, —NR10CO2R7, —SOR7, —SO2R7, —SO2NR10R10, and —NR10SO2R7;
q is 1, 2 or 3;
each R6 is independently selected from the group consisting of cyano, halo, C1-6 alkyl, C1-6 haloalkyl, and —CH2OH;
R7 is C1-6 alkyl or C1-6 haloalkyl;
R8 is hydrogen or C1-6 alkyl;
each R10 is independently hydrogen or C1-6 alkyl, or two R10 together with the atom(s) attached thereto form a 4- to 6-membered ring; and
R11 is hydrogen or R3.

### Claim 9 (depends on 5, 6, 7)

The method of any one of claims 5-7, wherein the neuronal disease or disorder is selected from Alzheimer's disease, Parkinson's disease, Parkinson's dementia, autism, fragile X syndrome, depression, and traumatic brain injury.

### Claim 10 (depends on 5, 6, 7)

The method of any one of claims 5-7, wherein the neuronal disease or disorder is Alzheimer's disease.

### Claim 11 (depends on 5, 6, 7)

The method of any one of claims 5-7, wherein the neuronal disease or disorder is depression.

### Claim 12

A method of promoting spinogenesis in a patient, comprising administering to a patient in need thereof a therapeutically effective amount of N-(1-(4-(trifluoromethyl)benzyl)-1H-indazol-3-yl)furan-2-carboxamide (compound 1), having the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 13

A method of treating a depression in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound selected from a compound of formula II, formula IV, formula V, formula VII, formula VIII, formula IX, formula X, or formula XI, or a pharmaceutically acceptable salt thereof, or compound 1, compound 8, compound 9, compound 10, or compound 11, or a pharmaceutically acceptable salt thereof.

### Claim 14

A method of treating depression comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I:
or a pharmaceutically acceptable salt thereof;
wherein A1, A2, A3, A4, A5 and A6 are independently selected from the group consisting of CH, CR3 and N, provided that no more than four of A1, A2, A3, A4, A5 and A6 are N;
R1 is selected from the group consisting of phenyl, 5-membered heteroaryl and 6-membered heteroaryl, wherein the phenyl, 5-membered heteroaryl or 6-membered heteroaryl is optionally substituted with 1 to 3 R6;
L2 is selected from the group consisting of a covalent bond, —NR8—, —C(O)NR8—, —NR8—, —C(O)NR8—, —NR8C(O)—, —C(O)CR82—, —CR82C(O)—, —NR8CR82—, and —CR82NR8—;
R2 is H, C1-6 alkyl, 6- to 10-membered aryl or 5- to 10-membered heteroaryl; wherein the 6- to 10-membered aryl or 5- to 10-membered heteroaryl is optionally substituted with 1 to 4 R4, wherein each R4 is independently selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, phenyl (optionally substituted with C1-6 alkyl, halo, C1-6 haloalkyl, or —OH), —OH, —OR7, —SH, —SR7, —NR10R10, halo, cyano, nitro, —COH, —COR7, —CO2H, —CO2R7, —CONR10R10, —OCOR7, —OCO2R7, —OCONR10R10, —NR10COR7, —NR10CO2R7, —SOR7, —SO2R7, —SO2NR10R10, and —NR10SO2R7;
each R3 is independently selected from the group consisting of C1-6 alkyl, C1-6 haloalkyl, —OH, —OR7, —SH, —SR7, —NR10R10, halo, cyano, nitro, —COH, —COR7, —CO2H, —CO2R7, —CONR10R10, —OCOR7, —OCO2R7, —OCONR10R10, —NR10COR7, —NR10CO2R7, —SOR7, —SO2R7, —SO2NR10R10, and —NR10SO2R7;
q is 1, 2 or 3;
each R6 is independently selected from the group consisting of cyano, halo, C1-6 alkyl, C1-6 haloalkyl, and —CH2OH;
R7 is C1-6 alkyl or C1-6 haloalkyl;
R8 is hydrogen or C1-6 alkyl;
each R10 is independently hydrogen or C1-6 alkyl, or two R10 together with the atom(s) attached thereto form a 4- to 6-membered ring; and
R11 is hydrogen or R3.
